The most prominent contributor to Norgine's growth is MOVICOL®, which isEurope's leading prescription laxative.
Norgine is one of a handful of independent pharmaceutical companies with a genuinely pan-European base, having successfully developed during its106 year history to become a specialty pharmaceutical powerhouse.
At the end of 2011, Norgine employed over 1000 staff with over 400 in Sales and Marketing. They are supported by a strong Development team, Medical and Regulatory Affairs expertise and appropriate administrative functions. In 2011, Norgine’s net product sales were €247 million,
The most prominent contributor to Norgine's growth is MOVICOL, which is Europe's leading prescription laxative. Sales of Norgine’s bowel cleansing preparation, MOVIPREP®, are also growing rapidly. Launched in the US in 2006 and in Europe in 2007, MOVIPREP is already Norgine’s second largest product and is the European bowel cleansing sector leader and a leading brand worldwide.
Norgine's focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and supportive care. We currently market a number of products in our key therapeutic areas, e.g. MOVICOL for the treatment of chronic constipation and faecal impaction, MOVIPREP for bowel preparation prior to colonoscopy, FIVASA® for the treatment of ulcerative colitis and Crohn's Disease, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain.
Norgine has a highly active Development function and currently has more than 10 products at various stages of clinical development in our core areas of gastroenterology and hepatology. The Company is undertaking a significant clinical development programme both in the USA and Europe with NRL 972, a liver diagnostic. NRL 972 promises to provide a real advance in the diagnosis and staging of a variety of liver diseases including Non-Alcoholic Fatty Liver Disease (NAFLD) and cirrhosis, to the benefit of patients, their carers and society at large. We are also looking to further develop our new pipeline products such as CAMETOR® for the treatment of obesity and TZP101 licensed in from Tranzyme.